Overview of the relevance of PI3K pathway in HR-positive breast cancer
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
One of the hallmarks of hormone receptor (HR)-positive breast cancer is its dependence on the phosphatidylinositol-3-kinase (PI3K) pathway. Here, we review the epidemiologic, functional, and pharmacologic interactions between oncogenic PI3K and the estrogen receptor (ER). We discuss the epidemiology of PI3K pathway alterations, mechanisms of resistance to PI3K inhibitors, and the current mechanistic landscape of crosstalk between PI3K and ER, which provide the rationale for dual ER and PI3K inhibition and is now a standard of care in the treatment of ER+ PIK3CA-mutant metastatic breast cancer. We outline newer studies in this field that delineate the clinically relevant overlaps between PI3K and parallel signaling pathways, insulin signaling, and ER epigenetic modifiers. We also identify several caveats with the current data and propose new strategies to overcome these bottlenecks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 1×
“While these inhibitors have been approved, they have limited activity as monotherapy [62, 63], likely due to narrow therapeutic windows and activation of compensatory mechanisms involved in intrinsic and adaptive resistance.”
BackgroundEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“One of the first clinical evidences that supported the close interaction between the PI3K pathway and ER signaling came from the Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) phase III clinical trial that showed improvement in progressionfree survival (PFS) in ERþ BC patients treated with the mTOR inhibitor eve…”
BackgroundThe PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749 · cited 1×
“The PI3K pathway integrates extracellular signals that activate receptor tyrosine kinases (RTKs) and G-protein-coupled receptors (GPCRs) and is necessary for normal growth and proliferation [1].”
BackgroundAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 4×
“Most importantly, it has provided the molecular rationale for simultaneously targeting both pathways to achieve superior disease control culminating with the encouraging recent results of the phase III clinical trial targeting both ER and PI3Ka in BC patients with HRþ/PIK3CA mutations and FDA approval of the first PI3…”
BackgroundMethodInfluentialmTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · cited 1×
“A variety of kinases including MAPKs and downstream effectors of PI3K such as AKT and S6K directly phosphorylate ER leading to ligand-independent ER-dependent transcription [50, 52, 53].”
BackgroundFoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008) · Cell · doi:10.1016/j.cell.2008.01.018 · Cited by 983 · cited 1×
“ER binding to its target genes leads to recruitment of additional cooperating TFs and chromatin regulators which are critical for the function of this intricate network (referred to as the classical genomic signaling pathway) [38].”
BackgroundAKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Self-citationSuppression of insulin feedback enhances the efficacy of PI3K inhibitors
Hopkins, B. D., Pauli, C., Du, X., Wang, D. G., Li, X., Wu, D., Amadiume, S. C., Goncalves, M. D., Hodakoski, C., Lundquist, M. R., et al. (2018) · Nature · doi:10.1038/s41586-018-0343-4 · Cited by 706 · cited 1×
“In a recent report, mouse models of multiple cancers including ERþ BC showed increased blood glucose and insulin on treatment with a wide range of small molecule inhibitors of the PI3K pathway, including PI3Ka-specific inhibitors [35].”
BackgroundAronica, S. M., Kraus, W. L., & Katzenellenbogen, B. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8517 · Cited by 670 · cited 2×
“These RTKs re-stimulate PI3K by binding to the nSH2 and cSH2 (Src homology 2) domains of p85a, relieving its inhibition of p110a.”
BackgroundA Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Zhang, Y., Kwok-Shing Ng, P., Kucherlapati, M., Chen, F., Liu, Y., Tsang, Y. H., de Velasco, G., Jeong, K. J., Akbani, R., Hadjipanayis, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.013 · Cited by 626 · cited 1×
“There is also a long tail of less frequent mutations scattered across the PIK3CA gene, the majority of which lead to partial activation in biochemical and cellular models [14].”
BackgroundConvergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Self-citationCDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438 · cited 3×
“Inhibition of other targets such as cyclin-dependent kinases 4 and 6 (CDK4/6) can re-sensitize ERþ BC cells that exhibit primary or acquired resistance to alpelisib [30].”
BackgroundMiller, T. W., Balko, J. M., Fox, E. M., Ghazoui, Z., Dunbier, A., Anderson, H., Dowsett, M., Jiang, A., Smith, R. A., Maira, S.-M., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0101 · Cited by 346
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005747 · Cited by 332
Self-citation
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Self-citationPI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Brett, J. O., Spring, L. M., Bardia, A., & Wander, S. A. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01462-3 · Cited by 414
Marra, A., Trapani, D., Viale, G., Criscitiello, C., & Curigliano, G. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00197-2 · Cited by 317
Minireview: parabens exposure and breast cancer
Hager, E., Chen, J., & Zhao, L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031873 · Cited by 110
Metadata
- Authors
- Vasan, N., Toska, E., & Scaltriti, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 30
- Issue
- Suppl_10
- Pages
- x3-x11
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2994724934
- Cited by
- 164
- References
- 17
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.